Pertuzumab

證據等級: L5

預測適應症: 10 個

Pertuzumab: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer

One-Sentence Summary

Pertuzumab (Perjeta®) is an anti-HER2 monoclonal antibody already used in combination regimens for HER2-positive breast cancer. The TxGNN model's top prediction highlights progesterone-receptor (PR) positive breast cancer, supported by 10 clinical trials and 20 publications — but this signal largely reflects an existing biomarker subgroup within pertuzumab's known HER2-positive breast cancer use rather than a mechanistically novel indication. The drug is currently not marketed in New Zealand, and a Medsafe/TFDA package insert data gap blocks formal safety pre-assessment.

Quick Overview

Item	Content
Original Indication	HER2-positive breast cancer (inferred from evidence pack context — all cited pivotal trials, e.g. CLEOPATRA/APHINITY-class studies, use pertuzumab + trastuzumab + docetaxel in HER2+ disease)
Predicted New Indication	Progesterone-receptor positive breast cancer
TxGNN Prediction Score	99.93%
Evidence Level	L1
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed original mechanism-of-action data from DrugBank is not available (data gap). Based on the mechanistic rationale supplied in the evidence pack, pertuzumab is a monoclonal antibody that binds HER2 domain II, blocking HER2–HER3 heterodimerization and downstream signaling — a mechanism distinct from, and complementary to, trastuzumab's HER2 domain IV binding.

Importantly, the evidence pack's own rationale flags a key caveat: this predicted indication is not a true mechanistic extension. Every supporting trial (NeoSphere, APHINITY-class studies, the QL1209 biosimilar program, etc.) enrolled HER2-positive breast cancer patients and simply stratified outcomes by hormone-receptor status. PR-positive status is a biomarker subgroup within pertuzumab's existing HER2-positive breast cancer approval, not a mechanistically distinct new disease. Accordingly, any use must be constrained to the HER2-positive AND PR-positive population — extrapolation to HER2-negative/PR-positive breast cancer is not supported by this evidence.

Two related predictions in the same evidence pack (rank 3: PR-negative breast cancer, evidence level L1; rank 4: luminal A/B breast tumor, evidence level L2) reinforce this pattern — TxGNN is largely surfacing biomarker-defined sub-populations of the same underlying HER2-positive breast cancer indication, rather than genuinely new disease areas.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04629846	Phase 3	Completed	517	QL1209 (pertuzumab biosimilar) vs. reference pertuzumab + trastuzumab + docetaxel in HER2+/ER-PR-negative early or locally advanced breast cancer (Grade A)
NCT05802225	Phase 3	Active, not recruiting	398	BCD-178 biosimilar vs. Perjeta as neoadjuvant therapy for HER2+, ER/PR-negative breast cancer
NCT02326974	Phase 2	Active, not recruiting	164	T-DM1 + pertuzumab preoperative therapy studying HER2 heterogeneity impact in early-stage HER2+ breast cancer
NCT00545688	Phase 2	Completed	417	4-arm neoadjuvant regimen study (Herceptin/docetaxel/pertuzumab); pathological complete response as endpoint, relevant to HR stratification (Grade A)
NCT06131424	N/A (retrospective)	Completed	1151	Non-interventional study on HER2-low prevalence, characteristics and treatment patterns in metastatic breast cancer
NCT03058939	Phase 2	Withdrawn	0	Weekly neoadjuvant paclitaxel response rate in Nigerian women with breast cancer; not pertuzumab-specific
NCT02689921	Phase 2	Unknown	7	NEOADAPT: chemo-free neoadjuvant aromatase inhibitor + pertuzumab/trastuzumab in HR+/HER2+ localized breast cancer (Grade B, underpowered)
NCT03726879	Phase 3	Completed	454	IMpassion050: atezolizumab vs. placebo added to neoadjuvant ddAC-paclitaxel-trastuzumab-pertuzumab in early HER2+ breast cancer (Grade A)
NCT00999804	Phase 2	Active, not recruiting	128	TBCRC 023: lapatinib + trastuzumab ± endocrine therapy for 12 vs. 24 weeks in HER2-overexpressing breast cancer
NCT04675827	Phase 2	Terminated	139	DECRESCENDO: chemotherapy de-escalation with SC pertuzumab + trastuzumab in HER2+/ER-negative/node-negative early breast cancer (Grade B)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27179402	2016	RCT	Lancet Oncology	NeoSphere 5-year follow-up: neoadjuvant pertuzumab + trastuzumab + docetaxel improves pathological complete response in HER2+ breast cancer
28945833	2017	RCT	Annals of Oncology	WSG-ADAPT HER2+/HR- trial: 12-week neoadjuvant dual HER2 blockade ± weekly paclitaxel, efficacy/safety and predictive markers
38906970	2024	RCT	British Journal of Cancer	QL1209 (pertuzumab biosimilar) equivalence to reference pertuzumab in HER2+/ER-PR-negative breast cancer
37609714	2023	RCT	Future Oncology	DECRESCENDO: de-escalating chemotherapy in HER2+, ER-negative, node-negative early breast cancer
37166817	2023	RCT	JAMA Oncology	WSG-TP-II: neoadjuvant endocrine therapy + trastuzumab/pertuzumab vs. de-escalated chemotherapy in HR+/HER2+ early breast cancer
30106636	2018	RCT (Phase 2)	Journal of Clinical Oncology	PERTAIN: first-line trastuzumab + aromatase inhibitor ± pertuzumab in HER2+/HR+ metastatic or locally advanced breast cancer
35640077	2022	Review	Journal of Clinical Oncology	ASCO Guideline Update on systemic therapy for advanced HER2-positive breast cancer
28973704	2017	Review	Southern Medical Journal	Overview of neoadjuvant and adjuvant therapies across breast cancer molecular subtypes
40282499	2025	Cohort	Cancers	Adjuvant treatment proposal for pT1-T2N0M0 HER2-positive and ER/PR-positive breast cancer including targeted/anti-hormonal therapy
33902424	2022	Review	Endocrine, Metabolic & Immune Disorders Drug Targets	Review of immunotherapy options for breast cancer, including trastuzumab/pertuzumab context

New Zealand Market Information

Pertuzumab currently has no market authorization in New Zealand (market status: Not marketed; 0 licenses on record). No product/dosage-form information is available to summarize.

Cytotoxicity

Pertuzumab is a HER2-targeted therapy used in the treatment of breast cancer, so this section is included.

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-HER2 monoclonal antibody; not a conventional cytotoxic agent)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. A blocking data gap exists: the TFDA/Medsafe package insert (warnings, contraindications, drug interactions) has not yet been obtained, which currently prevents formal S1 safety pre-assessment.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Evidence level L1 (multiple completed Phase 3 RCTs) supports pertuzumab's efficacy in HER2-positive breast cancer, but the "PR-positive" label represents a biomarker subgroup of an existing indication rather than a novel repurposing signal, and use must be restricted to the HER2-positive AND PR-positive population. A blocking safety data gap (no package insert on file) currently prevents formal safety clearance.

To proceed, the following is needed:

TFDA/Medsafe package insert (warnings, contraindications, drug interactions) — currently blocking S1 safety assessment
Detailed mechanism-of-action data from DrugBank
Confirmation of HER2 status alongside PR status in target population definitions, to avoid inappropriate extrapolation to HER2-negative/PR-positive disease
New Zealand regulatory/market-entry assessment, given current unmarketed status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.